|
|
|
|
|
|
| Global CRO Offers Specialist Teams for Oncology Drug Development |
Raleigh, N.C., June 1, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, is attending the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4 in Chicago to discuss accelerating development in the quest to conquer cancer.
"We are excited to be taking part once again in this year's ASCO and its 'Building Bridges to Conquer Cancer' initiative," said Nicholas Kenny, PhD, Executive Vice President and General Manager, Global Oncology and Hematology at INC Research. "The pace of drug development is increasing, driving greater opportunity for patients, but also increased scrutiny and competition for the most critical clinical trials. With specialists located worldwide, INC Research provides biopharmaceutical companies access to the most appropriate patient populations and study sites to accelerate development from first in patient Phase I studies through to approval, ultimately leading to more widely available, and better, cancer treatments."
Since 2001, INC Research has played a lead role alongside biopharmaceutical companies worldwide in conducting cancer clinical trials and has active oncology clinical trials underway in more than 40 countries involving a team of 400 specialists focused exclusively on oncology clinical research. INC Research provides medical, surgical and radiation oncologists with experience in all major and rare solid tumor types, along with specialist teams for early phase oncology development and hematological malignancies. INC Research supports all levels and stages of clinical development with the full spectrum of Phase I to IV oncology services, as well as extensive early phase experience with innovative drugs and protocols, including Phase I/IIa transitional programs.
For more information about how INC Research's oncology research capabilities are bridging the gap between patients and better cancer treatments, please visit Booth # 20121 at ASCO or download our oncology fact sheet.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations (including pediatric and women's health). Our Trusted Process(R) methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1-513-345-1685
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
Topic: Press release summary
Source: INC Research, LLC
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
